Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 74

Similar articles for PubMed (Select 23824974)

1.

High MMP-9 activity levels in fragile X syndrome are lowered by minocycline.

Dziembowska M, Pretto DI, Janusz A, Kaczmarek L, Leigh MJ, Gabriel N, Durbin-Johnson B, Hagerman RJ, Tassone F.

Am J Med Genet A. 2013 Aug;161A(8):1897-903. doi: 10.1002/ajmg.a.36023. Epub 2013 Jul 3.

PMID:
23824974
2.
3.

Minocycline promotes dendritic spine maturation and improves behavioural performance in the fragile X mouse model.

Bilousova TV, Dansie L, Ngo M, Aye J, Charles JR, Ethell DW, Ethell IM.

J Med Genet. 2009 Feb;46(2):94-102. doi: 10.1136/jmg.2008.061796. Epub 2008 Oct 3.

PMID:
18835858
4.

Open-label add-on treatment trial of minocycline in fragile X syndrome.

Paribello C, Tao L, Folino A, Berry-Kravis E, Tranfaglia M, Ethell IM, Ethell DW.

BMC Neurol. 2010 Oct 11;10:91. doi: 10.1186/1471-2377-10-91.

5.

Matrix metalloproteinases and minocycline: therapeutic avenues for fragile X syndrome.

Siller SS, Broadie K.

Neural Plast. 2012;2012:124548. doi: 10.1155/2012/124548. Epub 2012 May 20. Review.

6.

Long-lasting effects of minocycline on behavior in young but not adult Fragile X mice.

Dansie LE, Phommahaxay K, Okusanya AG, Uwadia J, Huang M, Rotschafer SE, Razak KA, Ethell DW, Ethell IM.

Neuroscience. 2013 Aug 29;246:186-98. doi: 10.1016/j.neuroscience.2013.04.058. Epub 2013 May 7.

7.

Electrocortical changes associated with minocycline treatment in fragile X syndrome.

Schneider A, Leigh MJ, Adams P, Nanakul R, Chechi T, Olichney J, Hagerman R, Hessl D.

J Psychopharmacol. 2013 Oct;27(10):956-63. doi: 10.1177/0269881113494105. Epub 2013 Aug 27.

PMID:
23981511
8.

A randomized double-blind, placebo-controlled trial of minocycline in children and adolescents with fragile x syndrome.

Leigh MJ, Nguyen DV, Mu Y, Winarni TI, Schneider A, Chechi T, Polussa J, Doucet P, Tassone F, Rivera SM, Hessl D, Hagerman RJ.

J Dev Behav Pediatr. 2013 Apr;34(3):147-55. doi: 10.1097/DBP.0b013e318287cd17.

9.

The Fragile X mental retardation protein regulates matrix metalloproteinase 9 mRNA at synapses.

Janusz A, Milek J, Perycz M, Pacini L, Bagni C, Kaczmarek L, Dziembowska M.

J Neurosci. 2013 Nov 13;33(46):18234-41. doi: 10.1523/JNEUROSCI.2207-13.2013.

10.

Side effects of minocycline treatment in patients with fragile X syndrome and exploration of outcome measures.

Utari A, Chonchaiya W, Rivera SM, Schneider A, Hagerman RJ, Faradz SM, Ethell IM, Nguyen DV.

Am J Intellect Dev Disabil. 2010 Sep;115(5):433-43. doi: 10.1352/1944-7558-115.5.433.

11.

Excessive astrocyte-derived neurotrophin-3 contributes to the abnormal neuronal dendritic development in a mouse model of fragile X syndrome.

Yang Q, Feng B, Zhang K, Guo YY, Liu SB, Wu YM, Li XQ, Zhao MG.

PLoS Genet. 2012;8(12):e1003172. doi: 10.1371/journal.pgen.1003172. Epub 2012 Dec 27.

12.

Minocycline treatment reverses ultrasonic vocalization production deficit in a mouse model of Fragile X Syndrome.

Rotschafer SE, Trujillo MS, Dansie LE, Ethell IM, Razak KA.

Brain Res. 2012 Feb 23;1439:7-14. doi: 10.1016/j.brainres.2011.12.041. Epub 2011 Dec 31.

PMID:
22265702
13.

Fragile X: leading the way for targeted treatments in autism.

Wang LW, Berry-Kravis E, Hagerman RJ.

Neurotherapeutics. 2010 Jul;7(3):264-74. doi: 10.1016/j.nurt.2010.05.005. Review.

14.

Molecular and cellular aspects of mental retardation in the Fragile X syndrome: from gene mutation/s to spine dysmorphogenesis.

De Rubeis S, Fernández E, Buzzi A, Di Marino D, Bagni C.

Adv Exp Med Biol. 2012;970:517-51. doi: 10.1007/978-3-7091-0932-8_23. Review.

PMID:
22351071
15.

Genetic removal of matrix metalloproteinase 9 rescues the symptoms of fragile X syndrome in a mouse model.

Sidhu H, Dansie LE, Hickmott PW, Ethell DW, Ethell IM.

J Neurosci. 2014 Jul 23;34(30):9867-79. doi: 10.1523/JNEUROSCI.1162-14.2014.

16.

Epigenetic characterization of the FMR1 gene and aberrant neurodevelopment in human induced pluripotent stem cell models of fragile X syndrome.

Sheridan SD, Theriault KM, Reis SA, Zhou F, Madison JM, Daheron L, Loring JF, Haggarty SJ.

PLoS One. 2011;6(10):e26203. doi: 10.1371/journal.pone.0026203. Epub 2011 Oct 12.

17.

Fragile X syndrome and targeted treatment trials.

Hagerman R, Lauterborn J, Au J, Berry-Kravis E.

Results Probl Cell Differ. 2012;54:297-335. doi: 10.1007/978-3-642-21649-7_17. Review.

18.
19.

Mechanism-based treatments in neurodevelopmental disorders: fragile X syndrome.

Berry-Kravis E.

Pediatr Neurol. 2014 Apr;50(4):297-302. doi: 10.1016/j.pediatrneurol.2013.12.001. Epub 2013 Dec 4. Review.

PMID:
24518745
20.

Comprehensive analysis of ultrasonic vocalizations in a mouse model of fragile X syndrome reveals limited, call type specific deficits.

Roy S, Watkins N, Heck D.

PLoS One. 2012;7(9):e44816. doi: 10.1371/journal.pone.0044816. Epub 2012 Sep 11.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk